IV Diagnostics

IV Diagnostics, founded in 2012 , is a biotechnology startup focused on advancing early cancer detection using circulating tumor cells (CTCs) for improved prognosis and disease management. The company's slogan, "Advancing Early Cancer Detection with Circulating Tumor Cells for Improved Prognosis and Disease Management," encapsulates its core mission. IV Diagnostics aims to leverage advancements in detecting and characterizing CTCs to significantly impact early cancer detection. The ability to quantify CTCs holds promise in predicting outcomes of metastatic diseases, while identifying cancer stem cells, a subset of CTCs, is crucial in detecting metastasis and disease recurrence. IV Diagnostics received a Private Equity Round investment on June 5, 2014, with Lakeshore ArchAngels and St. Louis Arch Angels as the investors. Operating at the intersection of biotechnology, healthcare, and platforms, IV Diagnostics is poised to make significant strides in the field of cancer diagnostics and disease management.